Browse Subject Areas

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal

Effects of Pre-Meal Drinks with Protein and Amino Acids on Glycemic and Metabolic Responses at a Subsequent Composite Meal

  • Ulrika J. Gunnerud, 
  • Cornelia Heinzle, 
  • Jens J. Holst, 
  • Elin M. Östman, 
  • Inger M. E. Björck



Whey proteins have insulinogenic properties and the effect appears to originate from a specific postprandial plasma amino acid pattern. The insulinogenic effect can be mimicked by a specific mixture of the five amino acids iso, leu, lys, thr and val.


The objective was to evaluate the efficacy of pre-meal boluses of whey or soy protein with or without added amino acids on glycaemia, insulinemia as well as on plasma responses of incretins and amino acids at a subsequent composite meal. Additionally, plasma ghrelin and subjective appetite responses were studied.


In randomized order, fourteen healthy volunteers were served a standardized composite ham sandwich meal with either water provided (250 ml) during the time course of the meal, or different pre-meal protein drinks (PMPD) (100 ml provided as a bolus) with additional water (150 ml) served to the meal. The PMPDs contained 9 g protein and were based on either whey or soy protein isolates, with or without addition of the five amino acids (iso, leu, lys, thr and val) or the five amino acids + arg.


All PMPD meals significantly reduced incremental area for plasma glucose response (iAUC) during the first 60 min. All whey based PMPD meals displayed lower glycemic indices compared to the reference meal. There were no significant differences for the insulinemic indices. The early insulin response (iAUC 0–15 min) correlated positively to plasma amino acids, GIP and GLP-1 as well as to the glycemic profile. Additionally, inverse correlations were found between insulin iAUC 0–15 min and the glucose peak.


The data suggests that a pre-meal drink containing specific proteins/amino acids significantly reduces postprandial glycemia following a composite meal, in absence of elevated insulinemic excursions. An early phase insulinemic response induced by plasma amino acids and incretins appears to mediate the effect.

Trial Registration NCT01586780<NCT01586780>


In type 2 diabetes (T2D), hyperglycemia is associated with an increased risk of cardiovascular diseases, and reduction of postprandial glycemia has recently been suggested to be as important as lowering fasting blood glucose levels to reach optimal metabolic control and reduce risk of complications [1]. Several epidemiological studies indicate that a high intake of milk and dairy products reduces the risk of developing T2D, obesity and cardiovascular disease [2][5], and a possible protective mechanism has been ascribed to the protein fraction [6][8]. In previous studies we have demonstrated that whey protein, co-ingested with carbohydrates, stimulates insulin secretion and reduces postprandial glycemia in both healthy subjects as well as in T2D patients [9], [10]. The insulinogenic effect appears to be mediated through a specific postprandial amino acid (AA) pattern appearing in plasma following whey ingestion, with the highest responses found for lysine (lys), threonine (thr) and the branched chained amino acids (BCAA) leucine (leu), isoleucine (iso) and valine (val) [10]. Furthermore, the release of the incretin glucose-dependent insulinotropic polypeptide (GIP) was proposed to be a contributing factor [10]. Interestingly, we have previously demonstrated that the insulinogenic effect can be mimicked by ingestion of a mixture of the mentioned 5 AA alone, however in the absence of a GIP response [11]. Additionally, oral administration of these 5 AA for 8 weeks has previously shown to improve insulin resistance on mice [12], suggesting possible beneficial effects of these particular 5AA in a longer time span.

It has been observed that intake of 18 g whey concentrate significantly increases insulin response and lowers glycemia compared with white wheat bread or glucose control [10], [11]. It could be hypothesized that exchanging part of the whey for insulinogenic AA (iso, leu, lys, thr and val) might be useful to optimize an insulinogenic effect. Furthermore, arginine (arg) has been suggested to increase insulin sensitivity [13], and also when co-ingested with leu, enhance the pancreatic insulin secretion [14]. Arg supplementation could therefore be expected to increase potency of the previously tested mixture of 5 AA. Soy protein is rich in arg and soy is often used as a substitute for milk and dairy products. Additionally, soy protein has been suggested to have beneficial effects on insulin resistance and obesity [15] as well on satiety [16]. The possible effect of soy protein on insulin response and glycemic regulation is therefore also of interest.

The aim of the present study was to evaluate the efficacy of pre-meal drinks of whey or soy protein isolates, respectively, with or without supplementation with AAs on insulinemia and glycemic regulation at a subsequent composite challenging meal. A mixture of five AA (iso, leu, lys, thr and val) was tested alone or in combination with arg. The potential timing effect was investigated based on the assumption that providing the insulinogenic proteins and AA as a pre-meal bolus would promote early insulin release, thus reducing the subsequent glycemic excursion. In addition, the effects on AA, incretins and ghrelin in plasma, as well as subjective satiety were investigated.

Subjects and Methods

The protocol for this study and supporting CONSORT checklist and flow diagram are available as supporting information; see Protocol S1, Checklist S1 and Flow Diagram S1.

Ethic Statement

The study was approved by the Ethics Committee in Lund, Sweden (reference number 556/2008). All test subjects gave their informed written consent prior to inclusion and were aware of the possibility of withdrawing from the study at any time they desired.

Test Subjects and Study Design

14 healthy non-smoking volunteers (5 M, 9F) aged 20 to 28 y with normal body mass index (BMI; in kg/m2; 21.9±0.6; mean ± SEM) and not receiving any drug treatment participated in the study. All subjects had normal fasting plasma glucose concentrations (5.5±0.1 mmol/L; mean ± SEM) and no history of lactose malabsorption.

A randomized, single blind, within-subject trial was performed. The meals were provided as breakfasts on 7 different occasions in random order with approximately 1 week between each test. The subjects were instructed to eat a standardized meal, in the evening (between 21.00 and 22.00) prior to every test day, consisting of white wheat bread slices and an optional drink. Thereafter they were instructed to avoid eating and drinking anything but small amounts of water until the start of the test. Additionally they were asked to avoid alcohol, excessive physical activity and food rich in dietary fibers the day before each test. When the subjects arrived in the laboratory in the morning a peripheral catheter was inserted into an antecubital vein. After drawing a fasting blood (t = 0 min) sample the meals were served.

Tests and Reference Meals

The nutritional compositions of all the meals are shown in Table 1. The meals were all based on one and the same standardized composite meal (ham sandwiches) with either 250 ml water provided during the time course of the meal, or different pre-meal protein drinks (PMPD) (100 ml) served as bolus doses with additional 150 ml water during the meal. The test subjects were instructed to drink the PMPD as a bolus immediately prior to eating the composite meal. Altogether, the PMPD and the sandwich meal were to be consumed within 12 min.

Table 1. Serving sizes and nutritional compositions of the reference and test meals1.

The PMPDs contained 9 g of protein, respectively and had the following composition; 1) whey protein isolate (W); 2) W, iso, leu, lys, thr and val (W+5AA); 3)W+5AA and arg (W+6AA); 4) soy protein isolate (S); 5) S, iso, leu, lys, thr and val (S+5AA); 6) S+5AA and arg (S+6AA).

All meals contained 50 g available carbohydrates in the form of white wheat bread (WWB). The protein content differed between the meals with the reference meal containing 13.3 g, and W, W+5AA, S and S+5AA containing 22.3 g of protein and the W+6AA and S+6AA meals had 23.0 g protein. The whey and soy protein isolates were kindly provided by Arla Foods Ingredients amba (Viby J. Denmark) and Semper AB (Stockholm, Sweden), respectively. The amino acid content of the whey and soy proteins is shown in Table 2. The whey protein contained maximum 0.2% lactose according to the manufacturer. All AA were single L-amino acids of food grade. Thr, iso and arg were manufactured by Ajinomoto (Kawasaki, Japan), whereas val, leu and lys were bought at Sigma-Aldrich AB (Stockholm, Sweden).

Physiological Parameters and Subjective Rating of Appetite

Capillary blood samples were taken for plasma glucose analysis and venous blood was drawn for analysis of serum insulin, plasma ghrelin, free AA in plasma (p-AA), plasma glucagon-like peptide-1 (GLP-1) and GIP. However, GIP and GLP-1 were only analyzed for a subset of test meals; the reference, W, W+5 and the S meal, respectively. Moreover, the subjects were asked to repeatedly fill in their subjective feeling of fullness, hunger and desire to eat, respectively, using 100 mm Visual Analogue Scales (VAS). Glucose, insulin and subjective appetite ratings were measured at 0, 15, 30, 45, 60, 90, 120 and 180 min. Ghrelin was measured at 0, 30, 60, 90, 120 and 180 min, while p-AA were measured at 0, 15, 30, 45 and 60 min.

After sampling, capillary plasma glucose was analyzed immediately (Glucose 201+, Hemocue AB, Ängelholm, Sweden). Serum and plasma (EDTA) tubes were left on ice to rest for approximately 30 min before centrifugation for 10 min (1800 * g, 4°C). Thereafter, serum and plasma were immediately separated and the samples were frozen at −20°C until analysis. Insulin analysis was performed on an integrated immunoassay analyzer (CODA Open Microplate System; Bio-rad Laboratories, Hercules, CA, USA) using an enzyme immunoassay kit (Mercodia AB, Uppsala, Sweden). Ghrelin was analyzed using a radioimmunoassay kit (Linco research Inc., St. Charles, MO, USA). Free AA were purified by mixing 100 µl of 10% sulfosalicylic acid with 400 µl plasma to precipitate high-molecular-weight proteins according to the method of Pharmacia Biochrom Ltd (Cambridge, United Kingdom). The AA solutions were filtered before analyzing with an AA analyzer (Biochrom 30; Pharmacia Biochrom Ltd) by using ion-exchange chromatography. The AA were separated by using standard lithium citrate buffers of pH 2.80, 3.00, 3.15, 3.50 and 3.55. The postcolumn derivatization was performed with ninhydrin. The plasma concentration of aspartic acid and cysteine was close to the limit of detection and was therefore not evaluated.

Plasma GIP and GLP-1 concentrations were measured after extraction of plasma with 70% ethanol (by vol, final concentration). For the GIP radioimmunoassay [17], we used the C-terminal directed antiserum R 65, that cross-reacts fully with human GIP but not with so called GIP 8000, whose chemical nature and relation to GIP secretion is uncertain. Human GIP and 125I human GIP (70 MBq/nmol) were used for standards and tracers. The concentration of plasma GLP-1 was measured [18] against standards of synthetic GLP-1 7–36 amide by using antiserum code no. 89390, which is specific for the amidated carboxyl terminus of GLP-1 and, therefore, does not react with GLP-1 containing peptides from the pancreas. For both assays the sensitivity was <1 pmol/L, intraassay CV <6% at 20 pmol/L, and recovery of standard, added to plasma before extraction, ≈100% when corrected for losses inherent in the plasma extraction procedure.

Calculations and Statistical Methods

The results are expressed as means ± SEM and values of p≤0.05 were considered statistically significant. Fasting values of glucose, insulin, p-AA, ghrelin, GLP-1 and GIP were analyzed with a general linear model (ANOVA) using subject as a random variable. The incremental areas under the curve (iAUC) for glucose, insulin GIP, GLP-1and p-AA as well as the total areas under the curve (AUC) for ghrelin and the subjective appetite ratings were calculated for each subject and test meal, using the trapezoid model (GraphPad Prism, release 5.03, GraphPad software Inc, San Diego). The glycemic and insulinemic indices (GI and II) were calculated from the 120 min postprandial iAUC for plasma glucose and serum insulin, respectively, by using the ham sandwich meal as a reference (GI and II = 100). Incremental peaks (iPeak) for glucose and insulin were calculated as the maximum postprandial increase from baseline. The glycemic profile (GP), defined as the duration (up to 180 min) of the glucose curve divided with the iPeak of glucose, was calculated [19]. In cases where the glucose remained above fasting level for the entire 180 min, the duration value was set to 180 min. The insulinogenic index (IGI), defined as the insulin iAUC 0–45 min divided with the glucose iAUC 0–45 min was calculated. A high insulinogenic index (IGI; nmol/mmol) represents a high potential of insulin to lower glucose within the first 45 min postprandially [20]. For ghrelin, relative changes from nadir to the concentration at 180 min after commencing the test meals as well as the concentration at 180 min and the AUC 0–180 min were calculated, using the trapezoid model.

The data were analyzed using a mixed model ANCOVA with subject as a random variable and the corresponding baseline (fasting values) as a covariate. Differences between groups were identified using Tukey’s multiple comparisons tests (MINITAB, release 14, Minitab Inc., State College, PA). In the cases of unevenly distributed residuals (tested with Anderson-Darling test), Box-Cox transformations were performed on the data prior to the ANOVA and/or ANCOVA, respectively.

Time x treatment interactions for glucose, insulin, subjective appetite ratings, ghrelin, GIP and GLP-1 as well as p-AA responses were analyzed using a mixed model (PROC MIXED in SAS release 8.01, SAS institute Inc., Cary, NC) with repeated measures and an autoregressive covariance structure. Subjects were modeled as a random variable and corresponding baseline values (fasting values) were modeled as covariate. When significant interactions between treatment and time were found, Tukey’s multiple comparisons test were performed for each time point by using the MINITAB software.

Correlation analysis was conducted to evaluate the relation among dependent measures with the use of Spearman’s partial correlation coefficients controlling for subjects and corresponding baseline values (two-tailed test), (SPSS software, version 18; SPSS Inc., Chicago, IL, USA).

Due to a standard preparation mistake during some of the AA analysis, a correction using a reduction of the concentrations by 22% was necessary. One subject did not consume the W+6AA and S+6AA meals and is therefore not included in the analysis on these two meals. One subject had to be excluded from the S meal due to reported inappropriate behavior the day prior to the test day. One more subject was excluded from the W+5AA and W+6AA analysis due to the intake of antibiotics within two weeks before the test days. Due to the same reason another subject was excluded from the data analysis on S+6AA. One subject was also excluded from the insulinogenic index (IGI) on W+5AA, caused by a glucose area equal to zero at AUC 0–45, leading to an incalculable IGI. Furthermore, two subjects were excluded from the ghrelin due to missing values, one from the reference meal and one from the S.


Plasma Glucose Responses

The postprandial glucose responses are shown in Figure 1 and Tables 3 and 4. The three whey based PMPD (WB-PMPD) meals but not the soy based PMPD (SB-PMPD) meals displayed lower GIs (%) compared to the reference meal. All PMPD meals resulted in a significantly lower postprandial glucose response (iAUC) during the first 45 min (Table 4). A significant treatment (P<0.0001) and time x treatment interaction (P<0.0001) was found, and at 30 and 45 min, the glucose responses were lower following all PMPD meals compared to the reference meal. Furthermore, at 30 min the glucose response to S was higher than W+5AA, and at 45 min the glucose response of the S meal was higher than W+5AA as well as W+6AA. Additionally, the iPeak for glucose (Δ mmol/L) was lower following all PMPD meals in comparison to the reference. Moreover, the glycemic profile (GP; min.mmol−1.L−1.) was higher for the W, W+5AA, W+6AA and S+5AA meals, respectively, than for the reference meal (Table 3). The WB-PMPD meals induced lower GI’s (mean 61±9), higher GP’s (mean 114±15) and lower glucose iPeaks (mean 1.5±0.1) in comparison to the SB-PMPD meals (mean GI 74±12; mean GP 82±10; mean iPeak 1.9±0.2).

Figure 1. Postprandial plasma glucose responses.

Mean (± SEM) incremental postprandial changes (Δ) in plasma glucose in response to equal amounts of carbohydrates from a reference meal and the PMPD meals; n = 14 (n = 13 for S and S+6AA; n = 12 for W+6AA). Values with different letters are significantly different, P≤0.05 (ANCOVA followed by Tukey’s multiple comparisons test). A significant treatment effect (P<0.001) and a significant time x treatment interaction (P<0.001) was found. *At 60 min W induced a significantly lower glucose response than did the reference. S (soy protein isolate); S+5AA (S, iso, leu, lys, thr and val); S+6AA (S+5AA and arg); W (whey protein isolate); W+5AA (W, iso, leu, lys, thr and val); W+6AA (W+5AA and arg).

Table 4. Early postprandial incremental areas under the curve (iAUC) for plasma glucose and serum insulin responses1.

Serum Insulin Responses

The insulin responses are shown in Figure 2 and Tables 3 and 4. In the early postprandial phase, expressed as iAUC 0–30 min, the W+5AA resulted in a higher insulin response compared to the reference and S, respectively (Table 4). No significant differences were found between the meals neither in insulinemic index (II in %) nor in iPeak for insulin (Δ mmol/L) (Figure 2; Table 3). All PMPDs except for S induced higher IGI’s than the reference meal. Moreover, the WB-PMPD meals displayed higher IGIs (mean 0.45±0.11) compared to the SB-PMPD meals (mean 0.24±0.03) (Table 3).

Figure 2. Postprandial serum insulin responses.

Mean (± SEM) incremental postprandial changes (Δ) in serum insulin in response to equal amounts of carbohydrates from a reference meal and the PMPD meals; n = 14 (n = 13 for S and S+6AA; n = 12 for W+6AA). A significant treatment effect (P<0.001) but no time x treatment interaction was found. S (soy protein isolate); S+5AA (S, iso, leu, lys, thr and val); S+6AA (S+5AA and arg); W (whey protein isolate); W+5AA (W, iso, leu, lys, thr and val); W+6AA (W+5AA and arg).

Postprandial Plasma Amino Acid Responses

Except for asp, no differences were found in fasting p-AA concentrations. The postprandial iAUC 0–60 min are displayed in Table 5. The plasma responses of arg, iso, leu, lys, and val were higher following all PMPD meals compared to the reference meal. Thr was higher after all PMPD except for the S meal. The WB-PMPDs resulted in more pronounced p-AA responses compared to the SB-PMPDs. The W/S+5AA and W/S+6AA meals yielded higher p-AA responses than the W and the S meals alone.

Table 5. Incremental postprandial areas under the curve (iAUC 0–60 min) for the different plasma amino acids1.

Plasma Incretins

In Figure 3 the iAUC are shown. The GLP-1 response was higher at iAUC 0–15, 0–30 and 0–45, respectively, after W+5AA compared to the reference meal. No significant differences were found for GIP.

Figure 3. Postprandial plasma incretin responses.

Mean (± SEM) incremental postprandial changes in GIP (A) and GLP-1 (B) in response to equal amounts of carbohydrates from a reference meal and the PMPD meals; n = 14 (n = 13 for S and S+6AA; n = 12 for W+6AA). Significant treatment effects (P<0.0001) but no time x treatment interactions were found for neither GLP-1 nor GIP. S (soy protein isolate); W (whey protein isolate); W+5AA (W, iso, leu, lys, thr and val).

Subjective Appetite Ratings and Plasma Ghrelin Responses

No significant differences were found for the AUC’s between the PMPD meals and reference meal neither for feeling of fullness, feeling of hunger, desire to eat nor for ghrelin. No treatment effects or time x treatment interactions were found (0–180 min) for either of the subjective appetite parameters. The ghrelin levels following all meals decreased to a nadir occurring at 99.5±3.0 min postprandially. Relative changes from nadir to the concentration at 180 min after commencing the PMPDs, as well as the concentration at 180 min, and the AUC 0–180 min, showed no differences following the different PMPDs and reference meals.


Correlations are displayed in Table 6. In the early phase, expressed as iAUC 0–15 min, the insulin responses correlated positively to the p-AA (r = 0.71, P<0.001), GIP (r = 0.61, P<0.001) and GLP-1 (r = 0.36, P<0.012) as well as to the GP (r = 0.39, P<0.001). In addition, inverse correlations were observed between early insulin (iAUC 0–15 min) and the glucose iPeak (r = −0.28, P<0.001). Moreover, the p-AA (iAUC 0–15 min) were positively correlated to the GP (r = 0.44, P<0.001) and inversely correlated to the glucose iPeak (r = −0.35, P<0.001).

Table 6. Spearman’s partial correlation coefficients and P values controlling for subjects and corresponding baseline values (two-tailed test), for the relations between plasma amino acids, plasma incretins, serum insulin (iAUC 0–15 min, respectively), and plasma glucose (expressed as GI, GP and Glucose iPeak)1.


In the present study we showed that starting a meal by drinking an insulinogenic protein/AA drink significantly reduced the postprandial glycemic response to a subsequent composite meal. Interestingly, no differences were observed in insulinemic responses with respect to either iAUC 0–180 min or iPeak, although whey protein and the added AA (thr, lys, ile, leu and val) are known to be insulin secretagogues [11], [21], [22]. This effect on glycemia in the absence of differences in over-all course of insulinemia could be explained by a rapid early insulin response. Consequently, in the present study we found that the early incremental insulin response (iAUC 0–15 min) correlated negatively with the glucose iPeak, and positively with the GP. The WB-PMPD meals appeared to be somewhat more potent in lowering glycemia compared to the SB-PMPD meals. However, the SB-PMPD meals also demonstrated a positive metabolic effect and the observed glycemic reduction with soy protein is in accordance with previous studies in healthy subjects [30]. Furthermore, we found positive correlations between early p-AA (iAUC 0–15 min) and early insulin response (iAUC 0–15 min), as well as negative correlations between the p-AA and the blood glucose iPeak and the GI, respectively. Moreover, the GPs were higher following the AA-containing PMPDs compared to S, W and reference meals. Impairment of first phase insulin secretion has been recognized as an early sign of β-cell dysfunction in both T2D patients as well as in subjects with impaired glucose tolerance (IGT) [23], [24]. Interestingly, addition of essential AA to a diet in poorly regulated and elderly T2D patients improved metabolic control, lowered fasting blood glucose and insulin levels [25], [26]. Most of the insulinogenic AA trigger insulin secretion by mechanisms that differ from those that are glucose-mediated [27]. In T2D, the insulinogenic effects of AA may remain unaffected even after long-term diabetes [9], [28], indicating an interesting potential for use of proteins/AA for metabolic control of T2D. It could be hypothesized that an insulinogenic protein/AA drink could be beneficial with respect to glycemic regulation in both T2D and IGT subjects, since the insulinogenic effect of proteins and AA, appear only when co-ingested with carbohydrates. Thus, un-physiological hypoglycemic episodes that are commonly reported with drug treatment of T2D patients [29], are likely to be avoided.

Although the results in the present study are based upon acute postprandial responses, long term intake of the 5 AA on insulin resistance are known from animal studies [12] and it can be hypothesized that similar positive effects on insulin resistance and glycemic regulation might also be observed following a longer term intervention in human subjects. Additionally, the BCAA have shown to positively affect several metabolic pathways, and they were recently suggested to increase longevity in mice [30].

Interestingly, we also observed that the early GIP and GLP-1 (iAUC0–15 min) responses, correlated strongly with both the early insulin and p-AA responses. Consequently, p-AA as well as the incretins may have contributed to the insulin stimulating mechanism. Additionally, in the present study we found that the GLP-1-responses in the early postprandial phase (iAUC 0–15, 0–30 and 0–45 min), were significantly higher following W+5AA meal, compared to the reference meal. No such effects were observed with the W or the S meal, respectively, and the increased incretin secretion could possibly be ascribed the AA supplementation.

GLP-1 has been reported to display a biphasic postprandial response, with the first peak occurring already after 15–30 min [31]. Although the main part of the GLP-1 secreting L-cells are located in the distal ileum and colon, L-cells are found throughout the small intestine [32]. The L-cells in the proximal part of the gut could possibly be responsible for the early secretion, observed in the present study. Interestingly, GLP-1 does not only stimulate insulin release but has also been shown to preserve the β-cell function. Of relevance in this context is that the ability to secrete incretins are impaired in T2D patients [33], and GLP-1 analogues are increasingly used in T2D treatment [34], [35]. As judged from the present work, whey protein and certain AA may act as GLP-1 secretagogues. In addition, it has previously been shown that AA could have GIP stimulatory effects [36], [37]. Furthermore, in vitro studies of isolated pancreatic islets from mouse have indicated that whey protein exerts its insulinogenic effect by elevation of p-AA and GIP and GLP-1 [38]. In the present study we found no significant differences on GIP secretion following the W, the W+5AA, nor the S meal, in comparison to the reference meal. We have previously observed that whey protein, but not an AA-mix per se, enhanced GIP secretion when co-ingested with 25 g of carbohydrates [11]. However, in the present study the composite meal contributed with the double amount of available carbohydrates (50 g), 10 g of additional fat and the serving sizes of the whey protein was half of that served in the previous study (9 vs.18 g). Both carbohydrates and fat are known to stimulate GIP secretion [39], and in the present study the protein/AA-induced effect on GIP could be masked by the effect from the fat and carbohydrates in the composite meal.

In the present study, we also aimed to investigate the possible enhancing effect on insulin secretion by adding arg to the 5AA-mix (thr, lys, ile, leu and val). Arg has been reported to enhance the pancreatic insulin secretion when co-ingested with leu [14]. However, in the present study, no further increase in insulinemic response was observed with arg added compared to that seen with the 5AA-mix.

Low grade inflammation is suggested as one contributing factor in the development of T2D [40], [41]. Markers of low-grade inflammation appears to be promoted by high postprandial blood glucose levels [42], implying that tight glycemic regulation may be advantageous in this context. Interestingly, it has been shown that high GI meals (white wheat bread or glucose) are more potent drivers of acute inflammation (nuclear factor κB) compared to low GI meals (pasta) in young healthy subjects [43]. Addition of the PMPD to a composite meal in the present study, significantly lowered the glycemic excursion and could therefore possibly lower postprandial inflammation, but further research in this field is required.

No significant differences were found for the subjective appetite parameters or ghrelin in the present study. Both whey and soy proteins have previously been ascribed satiating properties [15], [44]. It has also been postulated that whey protein induce higher short term satiety than carbohydrates and fat, respectively [45]. The lack of satiating effects of the test meals in this study is probably due a small number of participants, and to the low overall protein content.

There were some limitations of the study that need to be addressed. The female participant’s menstrual cycle stages were not screen for and possible influences of hormonal changes cannot be ruled out. The amount of protein in W+6AA and S+6AA was 0.7 g higher compared to the other meals, due to the arginine addition. Increased protein content could be expected to increase the insulinogenic effect. However, no such effect was found. Another limitation is that the entire volume of water (250 ml) was taken along with the sandwiches in the case of the reference meal, not as a pre-meal drink. However, previous studies have shown that neither volume nor timing of drinking the water affects the postprandial glycemia [46].


The reduction in postprandial glycemia seen after intake of pre-meal drinks consisting of whey and soy protein, with or without supplementation of an insulinogenic AA-mix (iso, leu, lys, thr and val) was substantial (up to about 47%) and was mediated by a significant increase in the very early postprandial insulin response. The early insulin response correlated to the early appearance of specific AA and GLP-1 in plasma, indicating the involvement also of this incretin. It is concluded that the enclosure of specific proteins and AA in a pre-meal drink offers an interesting strategy to attenuate postprandial glycemic excursions and promote release of the antidiabetic incretin GLP-1.


For his analytical help with the AA-analysis, we thank MSc Puneeth Kumar Kollipara.

Author Contributions

Conceived and designed the experiments: UG EÖ IB. Performed the experiments: UG CH. Analyzed the data: UG CH EÖ IB. Wrote the paper: UG CH EÖ IB. Responsible for the incretin analysis: JJH.


  1. 1. Ceriello A, Colagiuri S, Gerich J, Tuomilehto J (2008) Guideline Development G (2008) Guideline for management of postmeal glucose. Nutr Metab Cardiovasc Dis 18: S17–33.
  2. 2. Azadbakht L, Mirmiran P, Esmaillzadeh A, Azizi F (2005) Dairy consumption is inversely associated with the prevalence of the metabolic syndrome in Tehranian adults. American Journal of Clinical Nutrition 82: 523–530.
  3. 3. Malik VS, Sun Q, van Dam RM, Rimm EB, Willett WC, et al. (2011) Adolescent dairy product consumption and risk of type 2 diabetes in middle-aged women. American Journal of Clinical Nutrition 94: 854–861.
  4. 4. Warensjo E, Nolan D, Tapsell L (2010) Dairy Food Consumption and Obesity-Related Chronic Disease. In: Steve LT, editor. Advances in Food and Nutrition Research: Academic Press. 1–41.
  5. 5. Ruidavets JB, Bongard V, Dallongeville J, Arveiler D, Ducimetiere P, et al. (2007) High consumptions of grain, fish, dairy products and combinations of these are associated with a low prevalence of metabolic syndrome. Journal of Epidemiology and Community Health 61: 810–817.
  6. 6. Pfeuffer M, Schrezenmeir J (2007) Milk and the metabolic syndrome. Obes Rev 8: 109–118.
  7. 7. Luhovyy BL, Akhavan T, Anderson GH (2007) Whey proteins in the regulation of food intake and satiety. Journal of the American College of Nutrition 26: 704S–712S.
  8. 8. Jauhiainen T, Korpela R (2007) Milk peptides and blood pressure. the Journal of Nutrition 137: 825S–829S.
  9. 9. Frid AH, Nilsson M, Holst JJ, Bjorck IM (2005) Effect of whey on blood glucose and insulin responses to composite breakfast and lunch meals in type 2 diabetic subjects. American Journal of Clinical Nutrition 82: 69–75.
  10. 10. Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM (2004) Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. American Journal of Clinical Nutrition 80: 1246–1253.
  11. 11. Nilsson M, Holst JJ, Bjorck IME (2007) Metabolic effects of amino acid mixtures and whey protein in healthy subjects: studies using glucose-equivalent drinks. American Journal of Clinical Nutrition 85: 996–1004.
  12. 12. Noguchi Y, Nishikata N, Shikata N, Kimura Y, Aleman JO, et al. (2010) Ketogenic essential amino acids modulate lipid synthetic pathways and prevent hepatic steatosis in mice. PLoS One 5: e12057.
  13. 13. Lucotti P, Monti L, Setola E, La Canna G, Castiglioni A, et al. (2009) Oral L-arginine supplementation improves endothelial function and ameliorates insulin sensitivity and inflammation in cardiopathic nondiabetic patients after an aortocoronary bypass. Metabolism 58: 1270–1276.
  14. 14. van Loon LJ, Saris WH, Verhagen H, Wagenmakers AJ (2000) Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. American Journal of Clinical Nutrition 72: 96–105.
  15. 15. Velasquez MT, Bhathena SJ (2007) Role of dietary soy protein in obesity. Int J Med Sci 4: 72–82.
  16. 16. Veldhorst M, Nieuwenhuizen A, Hochstenbach-Waelen A, Westerterp K, Engelen M, et al. (2009) Effects of high and normal soyprotein breakfasts on satiety and subsequent energy intake, including amino acid and ‘satiety’ hormone responses. European Journal of Nutrition 48: 92–100.
  17. 17. Krarup T, Madsbad S, Moody AJ, Regeur L, Faber OK, et al. (1983) Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics. Journal of Clinical Endocrinology and Metabolism 56: 1306–1312.
  18. 18. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535–539.
  19. 19. Rosen LA, Silva LO, Andersson UK, Holm C, Ostman EM, et al. (2009) Endosperm and whole grain rye breads are characterized by low post-prandial insulin response and a beneficial blood glucose profile. Nutr J 8: 42.
  20. 20. Orskov C, Wettergren A, Holst JJ (1996) Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scandinavian Journal of Gastroenterology 31: 665–670.
  21. 21. Graf S, Egert S, Heer M (2011) Effects of whey protein supplements on metabolism: evidence from human intervention studies. Curr Opin Clin Nutr Metab Care 14: 569–580.
  22. 22. Gannon MC, Nuttall FQ (2010) Amino acid ingestion and glucose metabolism–a review. IUBMB Life 62: 660–668.
  23. 23. Pfeifer MA, Halter JB, Porte D (1981) Insulin secretion in diabetes mellitus. The American Journal of Medicine 70: 579–588.
  24. 24. Festa A, Williams K, Hanley AJ, Haffner SM (2008) Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 57: 1638–1644.
  25. 25. Solerte SB, Fioravanti M, Locatelli E, Bonacasa R, Zamboni M, et al. (2008) Improvement of blood glucose control and insulin sensitivity during a long-term (60 weeks) randomized study with amino acid dietary supplements in elderly subjects with type 2 diabetes mellitus. American Journal of Cardiology 101: 82E–88E.
  26. 26. Solerte SB, Gazzaruso C, Bonacasa R, Rondanelli M, Zamboni M, et al. (2008) Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. American Journal of Cardiology 101: 69E–77E.
  27. 27. Ronner P, Naumann CM, Friel E (2001) Effects of glucose and amino acids on free ADP in betaHC9 insulin-secreting cells. Diabetes 50: 291–300.
  28. 28. van Loon LJ, Kruijshoop M, Menheere PP, Wagenmakers AJ, Saris WH, et al. (2003) Amino acid ingestion strongly enhances insulin secretion in patients with long-term type 2 diabetes. Diabetes Care 26: 625–630.
  29. 29. Tahrani AA, Piya MK, Kennedy A, Barnett AH (2010) Glycaemic control in type 2 diabetes: targets and new therapies. Pharmacology and Therapeutics 125: 328–361.
  30. 30. Valerio A, D’Antona G, Nisoli E (2011) Branched-chain amino acids, mitochondrial biogenesis, and healthspan: an evolutionary perspective. Aging (Albany NY) 3: 464–478.
  31. 31. Delzenne N, Blundell J, Brouns F, Cunningham K, De Graaf K, et al. (2010) Gastrointestinal targets of appetite regulation in humans. Obes Rev 11: 234–250.
  32. 32. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiological Reviews 87: 1409–1439.
  33. 33. Nauck M, Stockmann F, Ebert R, Creutzfeldt W (1986) Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diab tologia 29: 46–52.
  34. 34. Holst JJ, Vilsboll T, Deacon CF (2009) The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology 297: 127–136.
  35. 35. Shyangdan DS, Royle P, Clar C, Sharma P, Waugh N, et al.. (2011) Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev: CD006423.
  36. 36. Flatt PR, Kwasowski P, Howland RJ, Bailey CJ (1991) Gastric inhibitory polypeptide and insulin responses to orally administered amino acids in genetically obese hyperglycemic (ob/ob) mice. the Journal of Nutrition 121: 1123–1128.
  37. 37. Thomas FB, Sinar D, Mazzaferri EL, Cataland S, Mekhjian HS, et al. (1978) Selective release of gastric inhibitory polypeptide by intraduodenal amino acid perfusion in man. Gastroenterology 74: 1261–1265.
  38. 38. Salehi AS, Gunnerud UJ, J MS, Östman EM, Holst JJ, et al.. (2012) The insulinogenic effect of whey protein is partially mediated by a direct effect of amino acids and GIP on beta-cells. Nutrition and Metabolism: in press.
  39. 39. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132: 2131–2157.
  40. 40. Laaksonen DE, Niskanen L, Nyyssonen K, Punnonen K, Tuomainen TP, et al. (2004) C-reactive protein and the development of the metabolic syndrome and diabetes in middle-aged men. Diab tologia 47: 1403–1410.
  41. 41. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, et al. (2006) Inflammatory process in type 2 diabetes: The role of cytokines. Annals of the New York Academy of Sciences 1084: 89–117.
  42. 42. Calder PC, Ahluwalia N, Brouns F, Buetler T, Clement K, et al. (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. British Journal of Nutrition 106 Suppl 3S5–78.
  43. 43. Dickinson S, Hancock DP, Petocz P, Ceriello A, Brand-Miller J (2008) High-glycemic index carbohydrate increases nuclear factor-kappaB activation in mononuclear cells of young, lean healthy subjects. American Journal of Clinical Nutrition 87: 1188–1193.
  44. 44. Veldhorst MA, Nieuwenhuizen AG, Hochstenbach-Waelen A, van Vught AJ, Westerterp KR, et al. (2009) Dose-dependent satiating effect of whey relative to casein or soy. Physiology and Behavior 96: 675–682.
  45. 45. Anderson GH, Moore SE (2004) Dietary proteins in the regulation of food intake and body weight in humans. the Journal of Nutrition 134: 974S–979S.
  46. 46. Gregersen S, Rasmussen O, Winther E, Hermansen K (1990) Water volume and consumption time: influence on the glycemic and insulinemic responses in non-insulin-dependent diabetic subjects. American Journal of Clinical Nutrition 52: 515–518.